Hon Wai Koon

Prof. Hon Wai Koon

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2011 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
Hon Wai KoonHon Wai Koon
Hon Wai Koon
DSDavid Q. Shih
David Q. Shih
JCJeremy Chen
Jeremy Chen
KBKyriaki Bakirtzi
Kyriaki Bakirtzi
THTressia C. Hing
Tressia C. Hing
CPCharalabos Pothoulakis
Charalabos Pothoulakis

1 January 2015 in Cellular and Molecular Gastroenterology and Hepatology
Verified
Journal Article
Open access
JYJun Hwan Yoo
Jun Hwan Yoo
SHSamantha Ho
Samantha Ho
DTDeanna Hoang-Yen Tran
Deanna Hoang-Yen Tran
MCMichelle Cheng
Michelle Cheng
KBKyriaki Bakirtzi
Kyriaki Bakirtzi
Hon Wai KoonHon Wai Koon
Hon Wai Koon
Cathelicidin (LL-37 in human and mCRAMP in mice) represents a family of endogenous antimicrobial peptides with anti-inflammatory effects. LL-37 also suppresses collagen synthesis, an important fibrotic response, in dermal fibroblasts. Here, we determined whether exogenous cathelicidin administration modulates intestinal fibrosis in two animal models of intestinal inflammation and in human colonic fibroblasts. C57BL/6J mice (n = 6 per group) were administered intracolonically with a trinitrobenzene sulphonic acid (TNBS) enema to induce chronic (6–7 weeks) colitis with fibrosis. We administered mCRAMP peptide (5 mg/kg every 3 day, week 5–7) or cathelicidin gene (Camp)-expressing lentivirus (107 infectious units week 4) intracolonically or intravenously, respectively. We then infected 129Sv/J mice with Salmonella typhimurium orally to induce cecal inflammation with fibrosis. Camp-expressing lentivirus (107 infectious units day 11) was administered intravenously. TNBS-induced chronic colitis was associated with increased colonic collagen (col1a2) mRNA expression. Intracolonic cathelicidin (mCRAMP peptide) administration or intravenous delivery of lentivirus-overexpressing cathelicidin gene significantly reduced colonic col1a2 mRNA expression in TNBS-exposed mice compared with vehicle administration. Salmonella infection also caused increased cecal inflammation associated with collagen (col1a2) mRNA expression that was prevented by intravenous delivery of Camp-expressing lentivirus. Exposure of human primary intestinal fibroblasts and human colonic CCD-18Co fibroblasts to transforming growth factor-β1 (TGF-β1) and/or insulin-like growth factor 1 induced collagen protein and mRNA expression, which was reduced by LL-37 (3–5 μM) through a MAP kinase-dependent mechanism. Cathelicidin can reverse intestinal fibrosis by directly inhibiting collagen synthesis in colonic fibroblasts.

2 February 2022 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
RLRocco Latorre
Rocco Latorre
AHAlan Hegron
Alan Hegron
CPChloe J. Peach
Chloe J. Peach
STShavonne Teng
Shavonne Teng
RTRaquel Tonello
Raquel Tonello
NBNigel W. Bunnett
Nigel W. Bunnett
G protein–coupled receptors (GPCRs) regulate many pathophysiological processes and are major therapeutic targets. The impact of disease on the subcellular distribution and function of GPCRs is poorly understood. We investigated trafficking and signaling of protease-activated receptor 2 (PAR 2 ) in colitis. To localize PAR 2 and assess redistribution during disease, we generated knockin mice expressing PAR 2 fused to monomeric ultrastable green fluorescent protein (muGFP). PAR 2 -muGFP signaled and trafficked normally. PAR 2 messenger RNA was detected at similar levels in Par 2 -mugfp and wild-type mice. Immunostaining with a GFP antibody and RNAScope in situ hybridization using F2rl1 (PAR 2 ) and Gfp probes revealed that PAR 2 -muGFP was expressed in epithelial cells of the small and large intestine and in subsets of enteric and dorsal root ganglia neurons. In healthy mice, PAR 2 -muGFP was prominently localized to the basolateral membrane of colonocytes. In mice with colitis, PAR 2 -muGFP was depleted from the plasma membrane of colonocytes and redistributed to early endosomes, consistent with generation of proinflammatory proteases that activate PAR 2 . PAR 2 agonists stimulated endocytosis of PAR 2 and recruitment of Gα q , Gα i , and β-arrestin to early endosomes of T84 colon carcinoma cells. PAR 2 agonists increased paracellular permeability of colonic epithelial cells, induced colonic inflammation and hyperalgesia in mice, and stimulated proinflammatory cytokine release from segments of human colon. Knockdown of dynamin-2 ( Dnm2 ), the major colonocyte isoform, and Dnm inhibition attenuated PAR 2 endocytosis, signaling complex assembly and colonic inflammation and hyperalgesia. Thus, PAR 2 endocytosis sustains protease-evoked inflammation and nociception and PAR 2 in endosomes is a potential therapeutic target for colitis.

1 November 2012 in Current Pharmaceutical Design
Verified
Journal Article
Closed access
PDF file
SHSamantha Ho
Samantha Ho
CPCharalabos Pothoulakis
Charalabos Pothoulakis
Hon Wai KoonHon Wai Koon
Hon Wai Koon
Antimicrobial peptides (AMPs) are important components of innate immunity. They are often expressed in response to colonic inflammation and infection. Over the last several years, the roles of several antimicrobial peptides have been explored. Gene expression of many AMPs (beta defensin HBD2-4 and cathelicidin) is induced in response to invasion of gut microbes into the mucosal barrier. Some AMPs are expressed in a constitutive manner (alpha defensin HD 5-6 and beta defensin HBD1), while others (defensin and bactericidal/ permeability increasing protein BPI) are particularly associated with Inflammatory Bowel Disease (IBD) due to altered defensin expression or development of autoantibodies against Bactericidal/permeability increasing protein (BPI). Various AMPs have different spectrum and strength of antimicrobial effects. Some may play important roles in modulating the colitis (cathelicidin) while others (lactoferrin, hepcidin) may represent biomarkers of disease activity. The use of AMPs for therapeutic purposes is still at an early stage of development. A few natural AMPs were shown to be able to modulate colitis when delivered intravenously or intracolonically (cathelicidin, elafin and SLPI) in mouse colitis models. New AMPs (synthetic or artificial non-human peptides) are being developed and may represent new therapeutic approaches against colitis. This review discusses the latest research developments in the AMP field with emphasis in innate immunity and pathophysiology of colitis.

12 May 2017 in BMC Gastroenterology
Verified
Journal Article
Open access
PDF file
DTDiana Hoang-Ngoc Tran
Diana Hoang-Ngoc Tran
JWJiani Wang
Jiani Wang
CHChristina Ha
Christina Ha
WHWendy Ho
Wendy Ho
SMS. Anjani Mattai
S. Anjani Mattai
Hon Wai KoonHon Wai Koon
Hon Wai Koon
Cathelicidin (LL-37) is an antimicrobial peptide known to be associated with various autoimmune diseases. We attempt to determine if cathelicidin can accurately reflect IBD disease activity. We hypothesize that serum cathelicidin correlates with mucosal disease activity, stricture, and clinical prognosis of IBD patients. Serum samples were collected from two separate cohorts of patients at the University of California, Los Angeles. Cohort 1 consisted of 50 control, 23 UC, and 28 CD patients. Cohort 2 consisted of 20 control, 57 UC, and 67 CD patients. LL-37 levels were determined by ELISA. Data from both cohorts were combined for calculation of accuracies in indicating mucosal disease activity, relative risks of stricture, and odds ratios of predicting disease development. Serum cathelicidin levels were inversely correlated with Partial Mayo Scores of UC patients and Harvey-Bradshaw Indices of CD patients. Among IBD patients with moderate or severe initial disease activity, the patients with high initial LL-37 levels had significantly better recovery than the patients with low initial LL-37 levels after 6–18 months, suggesting that high LL-37 levels correlate with good prognosis. Co-evaluation of LL-37 and CRP levels was more accurate than CRP alone or LL-37 alone in the correlation with Mayo Endoscopic Score of UC patients. Low LL-37 levels indicated a significantly elevated risk of intestinal stricture in CD patients. Co-evaluation of LL-37 and CRP can indicate mucosal disease activity in UC patients. LL-37 can predict future clinical activity in IBD patients and indicate risk of intestinal stricture in CD patients.

10 May 2016 in International Journal of Obesity
Verified
Journal Article
Open access
PDF file
DTD Hoang-Ngoc Tran
D Hoang-Ngoc Tran
SMS A Mattai
S A Mattai
TST Sallam
T Sallam
COC Ortiz
C Ortiz
ELE C Lee
E C Lee
Hon Wai KoonHon Wai Koon
Hon Wai Koon
Background and objectives: Obesity is a global epidemic which increases the risk of the metabolic syndrome. Cathelicidin (LL-37 and mCRAMP) is an antimicrobial peptide with an unknown role in obesity. We hypothesize that cathelicidin expression correlates with obesity and modulates fat mass and hepatic steatosis. Materials and methods: Male C57BL/6 J mice were fed a high-fat diet. Streptozotocin was injected into mice to induce diabetes. Experimental groups were injected with cathelicidin and CD36 overexpressing lentiviruses. Human mesenteric fat adipocytes, mouse 3T3-L1 differentiated adipocytes and human HepG2 hepatocytes were used in the in vitro experiments. Cathelicidin levels in non-diabetic, prediabetic and type II diabetic patients were measured by enzyme-linked immunosorbent assay. Results: Lentiviral cathelicidin overexpression reduced hepatic steatosis and decreased the fat mass of high-fat diet-treated diabetic mice. Cathelicidin overexpression reduced mesenteric fat and hepatic fatty acid translocase (CD36) expression that was reversed by lentiviral CD36 overexpression. Exposure of adipocytes and hepatocytes to cathelicidin significantly inhibited CD36 expression and reduced lipid accumulation. Serum cathelicidin protein levels were significantly increased in non-diabetic and prediabetic patients with obesity, compared with non-diabetic patients with normal body mass index (BMI) values. Prediabetic patients had lower serum cathelicidin protein levels than non-diabetic subjects. Conclusions: Cathelicidin inhibits the CD36 fat receptor and lipid accumulation in adipocytes and hepatocytes, leading to a reduction of fat mass and hepatic steatosis in vivo. Circulating cathelicidin levels are associated with increased BMI. Our results demonstrate that cathelicidin modulates the development of obesity.